Skip to content

Ultragenyx Pharmaceutical Inc.

RARE· NasdaqCore metricsCIK 1515673

Pharmaceutical preparations551 peers

Last sale
Nov 6, 2026 · -0.87%
Market cap
$1.57B
101.92M shares
Filings
1,034
$173.00M
Q3 2026+20.2% FY25 yoy
-$118.00M
Q3 2026N/M FY25 yoy
-$110.00M
Q3 2026N/M FY25 yoy
-$341.00M
Q3 2026derivedN/M FY25 yoy
-$1.16
Q3 2026N/M FY25 yoy
$150.00M
Q3 2026+142.0% FY25 yoy
$1.57B
—
2.2×
—
-28.11%
—

Twelve months to Sep 30, 2026 · derived

Price

$15.4351.71%$16.52past year
Nov 6, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$673.00MFY 2025
$673.00M0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$673,000,000reported
FY 20242024-12-31$560,000,000reported
FY 20232023-12-31$434,000,000reported
FY 20222022-12-31$363,329,000reported
FY 20212021-12-31$351,406,000reported
FY 20202020-12-31$271,030,000reported
FY 20192019-12-31$103,714,000reported
FY 20182018-12-31$51,495,000reported
FY 20172017-12-31$2,612,000reported
FY 20162016-12-31$133,000reported

Segments

Revenue by Geography, FY2018 to FY2025FY2018North America · FY2018 · $45.34MAll other · FY2018 · $863.00KEurope · FY2018 · $5.29MFY2019North America · FY2019 · $86.44MAll other · FY2019 · $5.19MEurope · FY2019 · $12.09MFY2020North America · FY2020 · $237.67MLatin America · FY2020 · $12.05MAll other · FY2020 · $12.05MEurope · FY2020 · $21.32MFY2021North America · FY2021 · $301.11MLatin America · FY2021 · $23.64MAll other · FY2021 · $23.64MEurope · FY2021 · $26.66MFY2022North America · FY2022 · $281.09MLatin America · FY2022 · $44.71MEurope, Middle East, and Africa · FY2022 · $36.37MAsia-Pacific · FY2022 · $1.16MEurope · FY2022 · $36.37MJapan · FY2022 · $1.16MFY2023North America · FY2023 · $307.00MLatin America · FY2023 · $77.00MEurope, Middle East, and Africa · FY2023 · $48.00MAsia-Pacific · FY2023 · $2.00MEurope · FY2023 · $47.53MJapan · FY2023 · $2.22MFY2024North America · FY2024 · $340.00MLatin America · FY2024 · $131.00MEurope, Middle East, and Africa · FY2024 · $80.00MAsia-Pacific · FY2024 · $9.00MFY2025North America · FY2025 · $377.00MLatin America · FY2025 · $170.00MEurope, Middle East, and Africa · FY2025 · $108.00MAsia-Pacific · FY2025 · $18.00M
LineFY2025ShareChange
North America$377.00M56%+10.9%
Latin America$170.00M25%+29.8%
Europe, Middle East, and Africa$108.00M16%+35.0%
Asia-Pacific$18.00M2.7%+100.0%
All other———
Europe———
Japan———
Total$673.00M

From the 10-K filed Feb 18, 2026RARE

Pharmaceutical preparations

Ultragenyx Pharmaceutical Inc. is the 47th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Ultragenyx Pharmaceutical Inc. · CIK 1515673 · Engraved from SEC EDGAR